SEC Form 4 · accession 0001640455-18-000041
Jounce Therapeutics, Inc. · JNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elizabeth Trehu
Officer — Chief Medical Officer
Period of report
Mar 8, 2018
Accepted (ET)
Mar 12, 2018 · 7:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640455
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 8, 2018 | M | 4,545 | $4.02 | A | 4,545 | D | |
| Common StockF2 | Mar 8, 2018 | S | 4,545 | $25.06 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $4.02 | Mar 8, 2018 | M | 4,545 | D | — | Nov 12, 2025 | Common Stock | 4,545 | 242,260 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions.
- F2Represents the weighted average share price of an aggregate total of 4,545 shares sold in the price range of $25.00 to $25.20 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F325% of the option shares vested and became exercisable on November 3, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter.